Skip to main content
TipRanks
Go Ultimate75% OFF

ValiRx plc (VAL) AI Stock Analysis

7 Followers
GB:VAL

ValiRx plc

(LSE:VAL)

Select Model
Rating:49Neutral
Price Target:GBX 0.17â–²(9.03% Upside)
Action:reiterated
Date:11/11/26

The score is held down primarily by weak financial performance (minimal revenue, negative margins, persistent losses, and continued cash burn that is shrinking equity/assets). Technicals provide partial support with improving short-term momentum (price above key short-term averages and positive MACD), but valuation remains constrained by negative earnings and no dividend support.

Positive Factors
Very low leverageMinimal debt materially reduces interest and refinancing pressure, giving ValiRx greater financial flexibility than a highly leveraged biotech. Although the company remains loss-making, its limited borrowings reduce the risk that debt obligations accelerate cash depletion or constrain strategic choices.
Negative Factors
Declining, minimal revenueRevenue is both very small and declining, indicating that current commercial activity is not yet sufficient to support the operating base. This leaves ValiRx dependent on future asset progress, partnerships, or financing rather than demonstrating a self-sustaining revenue engine over the coming quarters.

ValiRx plc (VAL) vs. iShares MSCI United Kingdom ETF (EWC)

-50%-25%0%25%50%75%100%GB:VAL-34.04%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 2.05M
Dividend Yield
―
Average Volume (3M)
15.59M
Price to Earnings (P/E)
-0.8
Beta (1Y)
1.08
Revenue Growth
-34.36%
EPS Growth
57.45%
Country
UK
Employees
11
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

ValiRx plc Business Overview & Revenue Model

Company Description

ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat p...

ValiRx plc Financial Statement Overview

Summary

Financials reflect an early-stage, cash-burning biotech: very small and declining revenue, negative gross profit, persistent operating/net losses, and consistently negative operating and free cash flow. Low debt reduces solvency risk, but equity and assets are shrinking as losses accumulate.

Income Statement

18Very Negative

Balance Sheet

42Neutral

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2020
Income Statement
Total Revenue32.67K31.37K49.77K9,60000
Gross Profit-112.46K-6,250-217.22K-246.04K-224.27K-228.79K
EBITDA-1.49M-2.18M-1.86M-2.04M-2.38M-1.45M
Net Income-2.14M-2.23M-1.92M-2.04M-2.41M-1.55M
Balance Sheet
Total Assets2.77M2.63M4.26M3.13M3.98M3.52M
Cash, Cash Equivalents and Short-Term Investments970.56K791.61K1.56M174.68K1.14M593.67K
Total Debt01,39511.86K22.07K37.71K58.72K
Total Liabilities120.82K235.10K346.41K226.51K149.65K109.56K
Stockholders Equity3.13M2.86M4.32M3.22M4.05M3.60M
Cash Flow
Free Cash Flow-1.36M-1.52M-1.62M-2.08M-1.71M-1.26M
Operating Cash Flow-1.36M-1.51M-1.58M-1.77M-1.71M-1.26M
Investing Cash Flow-2,587-13.58K-38.16K-306.18K00
Financing Cash Flow1.81M759.35K3.00M1.12M2.26M7,343

ValiRx plc Technical Analysis

Technical Analysis SentimentPositive
Last Price0.15

Price Trends

50DMA0.14Positive
100DMA0.15Positive
200DMA0.21Negative

Market Momentum

MACD0.00Negative
RSI56.22Neutral
STOCH54.29Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Positive. The current price of 0.15 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.14, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 56.22 is Neutral, neither overbought nor oversold. The STOCH value of 54.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:VAL.

ValiRx plc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:VAL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:VALGB:VAL49NeutralGBP 2.05M-0.81-71.49%―-34.36%57.45%
GB:SCLPGB:SCLP48NeutralGBP 98.19M-4.63128.87%―-100.00%-30.39%
GB:SARGB:SAR47NeutralGBP 23.75M-6.04-188.01%――28.78%
GB:HEMOGB:HEMO46NeutralGBP 46.90M-3.76-409.57%――18.57%
GB:TCFGB:TCF42NeutralGBP 4.64M-1.70-93.92%――55.56%
GB:IMMGB:IMM37UnderperformGBP 17.59M-2.25-559.87%――5.62%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%GB:VALGB:TCFGB:IMMGB:SARGB:SCLPGB:HEMODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:VAL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:VALValiRx plc0.15-0.08-34.04%
GB:TCFEvgen Pharma0.17-0.04-19.05%
GB:IMMImmuPharma plc2.82-7.16-71.74%
GB:SARSareum Holdings14.500.755.45%
GB:SCLPScancell Holdings81.00-19.00-19.00%
GB:HEMOHemogenyx Pharmaceuticals Plc680.00-204.00-23.08%

ValiRx plc Corporate Events

Business Operations and StrategyM&A Transactions

ValiRx sees value boost from Ambrose’s AM-Pharma acquisition

Positive
Oct 21, 2026

ValiRx plc has highlighted the impact of Ambrose Healthcare Ltd’s acquisition of AM-Pharma on its own position, after Ambrose disclosed a deal worth up to €161 million that triggered a share price move in ValiRx. Through its 54.14% owned subsidiary V...

Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements

ValiRx tightens operations and bolsters cash as it refocuses pipeline and portfolio

Positive
Sep 15, 2026

ValiRx has tightened its operations in the first half of 2026, fully implementing a lean strategy that cut administrative costs and delivered additional annual savings, while refocusing Inaphaea BioLabs on supporting the company’s own pipeline throug...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026